Phytotherapy for rhinosinusitis: focus on natural essential oils

October 26, 2023
691
УДК:  616.211+616.216-002
Resume

Rhinosinusitis is a common disease in most countries of the world, which causes loss of productivity, a significant burden on society and the health care system. Experts recommend using phytotherapy for the treatment of rhinosinusitis, in particular, eucalyptus essential oil (cineole) and the complex herbal preparation Myrtol, which is registered in our country under the trade name Respero Myrtol and Respero Myrtol forte. The evidence that supports the effectiveness of these drugs in the treatment of rhinosinusitis are mentioned. Eucalyptus, orange, myrtle and lemon essential oils, which are part of the Myrtol line of drugs (Respero Myrtol, Respero Myrtol forte), are recommended by German and international recommendations (EPOS 2020) as an effective and safe herbal medicine for the treatment of rhinosinusitis.

References

  • 1. Fokkens W.J., Lund V.J., Hopkins C. et al. (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 58(Suppl. S29): 1–464. doi: 10.4193/Rhin20.600.
  • 2. Інструкція до препарату Респеро Миртол форте. compendium.com.ua/info/559948/686004/.
  • 3. Bachert C., Marple B., Schlosser R.J. et al. (2020) Adult chronic rhinosinusitis. Nat. Rev. Dis. Primers, 86(2020). doi.org/10.1038/s41572-020-00218-1.
  • 4. Chandorkar N., Tambe S., Aminb P. et al. (2021) A systematic and comprehensive review on current understanding of the pharmacological actions, molecular mechanisms, and clinical implications of the genus Eucalyptus/Phytomedicine Plus 1 (2021). doi.org/10.1016/j.phyplu.2021.100089.
  • 5. He X., Wei Z., Zhou E. et al. (2015) Baicalein attenuates inflammatory responses by suppressing TLR4 mediated NF-κB and MAPK signaling pathways in LPS-induced mastitis in mice. Int. Immunopharmacol., 28(1): 470–476. doi:10.1016/j.intimp.2015.07.012.
  • 6. Інформація, представлена компанією Berlin-Chemie. youtu.be/aHVlBoVMMwE.
  • 7. Kehrl W., Sonnemann U., Dethlefsen U. (2004) Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebocontrolled trial. Laryngoscope, 114: 738–742. doi.org/10.1097/00005537-200404000-00027.
  • 8. Werkhäuser N., Pieper-Fürst U., Sahin H. et al. (2023) Rhinosinusitis Treatment with Cineole: Patient-Reported Quality of Life Improvements from a Non-Interventional, Pharmacy-Based Survey. Medicines (Basel), 10(6): 37. doi: 10.3390/medicines10060037.
  • 9. Pfaar O., Beule A.G., Jobst D. et al. (2022) Phytomedicine ELOM‐080 in Acute Viral Rhinosinusitis: A Randomized, Placebo‐Controlled, Blinded Clinical Trial. The Laryngoscope, 133.
  • 10. Gottschlich S., Röschmann K., Candler H. (2018) Phytomedicines in Acute Rhinosinusitis: A Prospective, Non-interventional Parallel-Group Trial. Advances in Therapy, 35: 1023–1034.
  • 11. Fürst R., Luong B., Thomsen J. (2019) ELOM-080 as Add-On Treatment for Respiratory Tract Diseases — A Review of Clinical Studies Conducted in China. Planta Med., 85: 745–754. doi.org/10.1055/a-0942-1993.
  • 12. Chen D.Z. (2004) GeloMyrtol in the treatment of chronic sinusitis in children: a clinical observation study. Sichuan Med. J., 25: 806–807.
  • 13. Nai H.Y., Li Y., Bi J.L. (2008) The therapeutic effects of GeloMyrtol on children’s chronic nasosinusitis — a report of 85 cases. J. Nanhua University, 36: 370–371.
  • 14. Zhou G.F., Yang L.P., Shi J. (2010) Therapeutic effect of azithromycin with GeloMyrtol in the treatment of pediatric chronic sinusitis: an observational study. J. Dali University, 9: 47–48.
  • 15. Li Q. (2014) Efficacy of azithromycin in combination with GeloMyrtol in the treatment of chronic sinusitis in children. Chinese J. Rational Drug Use, 7: 64–65.
  • 16. Wu Y., Tang J. (2011) Therapeutic effects of Myrtol standardized enteric soft capsules in the treatment of pediatric chronic sinusitis. J. Clin. Med. Pract., 15: 86–87.
  • 17. Hoang M.P., Seresirikachorn K., Chitsuthipakorn W. et al. (2023) Herbal Medicines for Rhinosinusitis: A Systematic Review and Network Meta-analysis. Curr. Allergy Asthma Rep., 23: 93–109. doi.org/10.1007/s11882-022-01060-z.
  • 18. Poole P.J., Black P.N. (2001) Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ, 322: 1271–1274.
  • 19. DEGAM (2018) Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin. Leitline Nr. 11 Husten. http://www.awmf.org/uploads/tx_szleitlinien/053-013l_S3_Husten_2014-02-abgelaufen.pdf.
  • 20. Abholz H.H., Gillissen A., Magnussen H. et al. (2018) Nationale VersorgungsLeitlinie COPD. http://www.leitlinien.de/mdb/downloads/nvl/copd/archiv/copd-vers1.9-lang.pdf.
  • 21. Kardos P., Dinh Q.T., Fuchs K.H. et al. (2019) Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Pneumologie, 73: 143–118.
  • 22. Vogelmeier C., Buhl R., Criée C. et al. (2007) Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie, 61: e1–e40.